Robert Griffin
Concepts (745)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 38 | 2024 | 1334 | 4.870 |
Why?
| | Hyperthermia, Induced | 17 | 2019 | 114 | 3.390 |
Why?
| | Mammary Neoplasms, Experimental | 12 | 2015 | 122 | 3.040 |
Why?
| | Radiotherapy | 10 | 2021 | 126 | 2.770 |
Why?
| | Air Pollutants | 13 | 2024 | 75 | 2.690 |
Why?
| | Gold | 9 | 2023 | 81 | 2.480 |
Why?
| | Exosomes | 8 | 2026 | 58 | 2.430 |
Why?
| | Nanoparticles | 7 | 2026 | 133 | 2.210 |
Why?
| | Mice | 76 | 2026 | 5982 | 2.050 |
Why?
| | Animals | 103 | 2026 | 13526 | 1.980 |
Why?
| | Bystander Effect | 5 | 2024 | 25 | 1.950 |
Why?
| | Radiation-Sensitizing Agents | 11 | 2023 | 50 | 1.910 |
Why?
| | Cell Line, Tumor | 40 | 2026 | 1470 | 1.790 |
Why?
| | Nanostructures | 5 | 2023 | 41 | 1.720 |
Why?
| | Angiogenesis Inhibitors | 8 | 2017 | 186 | 1.470 |
Why?
| | Phototherapy | 5 | 2022 | 26 | 1.470 |
Why?
| | Radiation Tolerance | 9 | 2020 | 78 | 1.430 |
Why?
| | Metal Nanoparticles | 4 | 2023 | 67 | 1.390 |
Why?
| | Blood Vessels | 9 | 2020 | 73 | 1.370 |
Why?
| | Neoplasms, Experimental | 6 | 2020 | 112 | 1.320 |
Why?
| | Lung Neoplasms | 10 | 2024 | 645 | 1.310 |
Why?
| | Galectin 1 | 4 | 2017 | 19 | 1.300 |
Why?
| | Environmental Monitoring | 8 | 2024 | 75 | 1.270 |
Why?
| | Aerosols | 10 | 2023 | 74 | 1.270 |
Why?
| | Oxygen | 12 | 2020 | 338 | 1.240 |
Why?
| | Polyethylene Glycols | 4 | 2022 | 95 | 1.200 |
Why?
| | Air Pollution | 3 | 2024 | 49 | 1.170 |
Why?
| | Particulate Matter | 5 | 2024 | 66 | 1.150 |
Why?
| | Carcinoma, Squamous Cell | 6 | 2019 | 332 | 1.140 |
Why?
| | Humans | 115 | 2026 | 53230 | 1.090 |
Why?
| | Combined Modality Therapy | 17 | 2022 | 640 | 1.050 |
Why?
| | Mice, Inbred BALB C | 9 | 2026 | 310 | 1.020 |
Why?
| | Endothelial Cells | 7 | 2021 | 289 | 1.000 |
Why?
| | Tumor Necrosis Factor-alpha | 8 | 2019 | 392 | 0.970 |
Why?
| | Radiotherapy, Intensity-Modulated | 6 | 2025 | 181 | 0.960 |
Why?
| | Radiosurgery | 8 | 2024 | 133 | 0.940 |
Why?
| | Proteins | 7 | 2023 | 351 | 0.940 |
Why?
| | Sulfates | 2 | 2023 | 26 | 0.930 |
Why?
| | Neovascularization, Pathologic | 9 | 2021 | 158 | 0.930 |
Why?
| | Fibrosarcoma | 7 | 2019 | 16 | 0.930 |
Why?
| | Apoptosis | 10 | 2024 | 1139 | 0.920 |
Why?
| | Antineoplastic Agents | 13 | 2024 | 1232 | 0.860 |
Why?
| | Liposomes | 2 | 2022 | 55 | 0.850 |
Why?
| | Oxygen Consumption | 4 | 2020 | 201 | 0.830 |
Why?
| | Peptides | 10 | 2022 | 234 | 0.820 |
Why?
| | Ozone | 6 | 2022 | 21 | 0.820 |
Why?
| | Benzeneacetamides | 2 | 2024 | 12 | 0.800 |
Why?
| | Glutaminase | 2 | 2024 | 18 | 0.800 |
Why?
| | Fluorescent Dyes | 5 | 2022 | 90 | 0.800 |
Why?
| | Diamond | 1 | 2023 | 1 | 0.800 |
Why?
| | Microwaves | 1 | 2023 | 10 | 0.800 |
Why?
| | Cell Communication | 3 | 2021 | 73 | 0.790 |
Why?
| | Neoplastic Cells, Circulating | 3 | 2017 | 34 | 0.750 |
Why?
| | Pyrimidines | 10 | 2024 | 205 | 0.740 |
Why?
| | Indocyanine Green | 2 | 2013 | 29 | 0.740 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 5 | 2024 | 175 | 0.720 |
Why?
| | Flow Cytometry | 5 | 2017 | 400 | 0.710 |
Why?
| | Radiotherapy Dosage | 8 | 2025 | 249 | 0.690 |
Why?
| | Protein Kinase Inhibitors | 6 | 2024 | 233 | 0.680 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 8 | 2025 | 250 | 0.680 |
Why?
| | Cell Survival | 16 | 2024 | 600 | 0.670 |
Why?
| | Thiadiazoles | 3 | 2024 | 18 | 0.670 |
Why?
| | Conservation of Natural Resources | 6 | 2025 | 44 | 0.650 |
Why?
| | Carcinoma | 3 | 2025 | 136 | 0.650 |
Why?
| | Models, Theoretical | 9 | 2017 | 180 | 0.650 |
Why?
| | Antioxidants | 2 | 2020 | 264 | 0.630 |
Why?
| | Radiation-Protective Agents | 1 | 2020 | 69 | 0.620 |
Why?
| | Radiation Dosage | 2 | 2020 | 160 | 0.610 |
Why?
| | Immunotherapy | 2 | 2021 | 266 | 0.610 |
Why?
| | Female | 39 | 2026 | 28782 | 0.600 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 291 | 0.590 |
Why?
| | Ecosystem | 5 | 2017 | 99 | 0.560 |
Why?
| | Epigenesis, Genetic | 2 | 2019 | 412 | 0.560 |
Why?
| | Molecular Imaging | 2 | 2015 | 28 | 0.560 |
Why?
| | Information Dissemination | 2 | 2016 | 85 | 0.560 |
Why?
| | Drug Delivery Systems | 2 | 2022 | 148 | 0.560 |
Why?
| | Aniline Compounds | 5 | 2024 | 48 | 0.560 |
Why?
| | Arsenicals | 3 | 2007 | 15 | 0.550 |
Why?
| | Cell Proliferation | 12 | 2024 | 1031 | 0.550 |
Why?
| | Oxides | 3 | 2007 | 21 | 0.550 |
Why?
| | Uncertainty | 2 | 2022 | 46 | 0.540 |
Why?
| | Xenograft Model Antitumor Assays | 13 | 2021 | 228 | 0.530 |
Why?
| | Disease Models, Animal | 11 | 2020 | 1517 | 0.530 |
Why?
| | Gamma Rays | 2 | 2020 | 48 | 0.520 |
Why?
| | Bone and Bones | 2 | 2012 | 501 | 0.520 |
Why?
| | Oxidation-Reduction | 5 | 2023 | 333 | 0.520 |
Why?
| | Radiotherapy, Conformal | 2 | 2019 | 51 | 0.520 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 177 | 0.520 |
Why?
| | Coronavirus Infections | 1 | 2020 | 188 | 0.510 |
Why?
| | Mice, Nude | 12 | 2019 | 232 | 0.510 |
Why?
| | Science | 1 | 2016 | 22 | 0.500 |
Why?
| | Wind | 3 | 2025 | 7 | 0.500 |
Why?
| | Molecular Targeted Therapy | 3 | 2018 | 138 | 0.500 |
Why?
| | Radiobiology | 5 | 2023 | 21 | 0.490 |
Why?
| | Enzyme Inhibitors | 7 | 2024 | 371 | 0.480 |
Why?
| | Mouth Neoplasms | 4 | 2015 | 22 | 0.470 |
Why?
| | Texas | 7 | 2024 | 138 | 0.460 |
Why?
| | Pandemics | 1 | 2020 | 595 | 0.460 |
Why?
| | Cell Hypoxia | 6 | 2015 | 82 | 0.450 |
Why?
| | Laser Therapy | 2 | 2013 | 75 | 0.430 |
Why?
| | Exons | 3 | 2024 | 100 | 0.430 |
Why?
| | Solanum tuberosum | 1 | 2014 | 5 | 0.420 |
Why?
| | Tissue Distribution | 2 | 2026 | 174 | 0.420 |
Why?
| | Sanitation | 1 | 2014 | 17 | 0.420 |
Why?
| | Radiation Oncology | 3 | 2024 | 26 | 0.420 |
Why?
| | Bone Marrow Neoplasms | 1 | 2013 | 13 | 0.410 |
Why?
| | Coloring Agents | 2 | 2013 | 65 | 0.410 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2018 | 868 | 0.410 |
Why?
| | Chemokines | 1 | 2013 | 78 | 0.400 |
Why?
| | Spectrum Analysis, Raman | 3 | 2019 | 42 | 0.400 |
Why?
| | Plasmodium falciparum | 2 | 2024 | 26 | 0.400 |
Why?
| | Malaria, Falciparum | 2 | 2024 | 24 | 0.390 |
Why?
| | Infrared Rays | 2 | 2019 | 21 | 0.390 |
Why?
| | Tumor Cells, Cultured | 8 | 2019 | 441 | 0.390 |
Why?
| | Signal Transduction | 8 | 2021 | 1748 | 0.380 |
Why?
| | Tumor Microenvironment | 7 | 2022 | 274 | 0.380 |
Why?
| | Indoles | 4 | 2024 | 280 | 0.380 |
Why?
| | Cell Death | 7 | 2019 | 171 | 0.370 |
Why?
| | Antibodies, Monoclonal | 3 | 2020 | 477 | 0.370 |
Why?
| | Adult Stem Cells | 1 | 2012 | 12 | 0.370 |
Why?
| | DNA Damage | 5 | 2019 | 309 | 0.360 |
Why?
| | Lignin | 1 | 2011 | 2 | 0.360 |
Why?
| | Bone Neoplasms | 2 | 2011 | 188 | 0.350 |
Why?
| | Environmental Pollution | 1 | 2011 | 14 | 0.350 |
Why?
| | Time Factors | 12 | 2017 | 2991 | 0.350 |
Why?
| | Mice, Inbred C3H | 9 | 2015 | 81 | 0.350 |
Why?
| | Models, Biological | 6 | 2018 | 737 | 0.340 |
Why?
| | Dose-Response Relationship, Radiation | 10 | 2020 | 187 | 0.340 |
Why?
| | Photochemical Processes | 1 | 2010 | 5 | 0.340 |
Why?
| | Saliva | 3 | 2007 | 56 | 0.330 |
Why?
| | Photons | 2 | 2020 | 21 | 0.330 |
Why?
| | Cytokines | 1 | 2013 | 627 | 0.330 |
Why?
| | Phenols | 1 | 2011 | 94 | 0.330 |
Why?
| | Breast Neoplasms | 6 | 2017 | 1222 | 0.320 |
Why?
| | Melanoma, Experimental | 2 | 2021 | 34 | 0.320 |
Why?
| | Rats | 11 | 2022 | 3162 | 0.320 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2025 | 235 | 0.320 |
Why?
| | Cell Line | 6 | 2021 | 1016 | 0.320 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2023 | 250 | 0.320 |
Why?
| | Methionine | 3 | 2020 | 142 | 0.310 |
Why?
| | Mutagenesis, Insertional | 3 | 2024 | 24 | 0.310 |
Why?
| | Oceans and Seas | 3 | 2025 | 31 | 0.310 |
Why?
| | Radiation Injuries | 3 | 2020 | 114 | 0.300 |
Why?
| | Volatile Organic Compounds | 2 | 2022 | 8 | 0.300 |
Why?
| | Hydroxyl Radical | 2 | 2010 | 6 | 0.290 |
Why?
| | Glutamine | 3 | 2024 | 177 | 0.290 |
Why?
| | Atmosphere | 4 | 2019 | 11 | 0.290 |
Why?
| | Receptor, erbB-2 | 5 | 2016 | 79 | 0.290 |
Why?
| | Reactive Oxygen Species | 3 | 2024 | 421 | 0.290 |
Why?
| | Radiation | 2 | 2020 | 14 | 0.290 |
Why?
| | Drug Carriers | 2 | 2013 | 68 | 0.280 |
Why?
| | Weightlessness Simulation | 2 | 2020 | 22 | 0.280 |
Why?
| | Precancerous Conditions | 2 | 2010 | 87 | 0.280 |
Why?
| | Male | 22 | 2024 | 27435 | 0.280 |
Why?
| | History, 20th Century | 3 | 2020 | 97 | 0.280 |
Why?
| | Caspase Inhibitors | 1 | 2008 | 16 | 0.280 |
Why?
| | Cell Membrane Permeability | 1 | 2008 | 24 | 0.280 |
Why?
| | Mice, SCID | 3 | 2024 | 180 | 0.270 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 28 | 0.270 |
Why?
| | Cities | 3 | 2024 | 32 | 0.270 |
Why?
| | Forecasting | 4 | 2020 | 152 | 0.270 |
Why?
| | China | 3 | 2023 | 135 | 0.270 |
Why?
| | Nanomedicine | 2 | 2024 | 15 | 0.270 |
Why?
| | Carbon Radioisotopes | 2 | 2024 | 55 | 0.270 |
Why?
| | Freezing | 2 | 2004 | 15 | 0.270 |
Why?
| | Caspases | 1 | 2007 | 101 | 0.260 |
Why?
| | Adenocarcinoma | 1 | 2011 | 405 | 0.260 |
Why?
| | Nanotubes, Carbon | 2 | 2017 | 43 | 0.260 |
Why?
| | Vascular Neoplasms | 1 | 2007 | 17 | 0.260 |
Why?
| | Fisheries | 2 | 2025 | 10 | 0.250 |
Why?
| | Radiotherapy, Image-Guided | 2 | 2016 | 24 | 0.250 |
Why?
| | Glutathione | 2 | 2019 | 303 | 0.240 |
Why?
| | Microscopy, Fluorescence | 3 | 2018 | 140 | 0.240 |
Why?
| | Melanoma | 2 | 2020 | 277 | 0.240 |
Why?
| | Risk Assessment | 3 | 2017 | 1368 | 0.240 |
Why?
| | Cryotherapy | 2 | 2011 | 12 | 0.240 |
Why?
| | Nose Neoplasms | 1 | 2025 | 4 | 0.240 |
Why?
| | Brain | 3 | 2025 | 1350 | 0.240 |
Why?
| | Dog Diseases | 1 | 2025 | 11 | 0.230 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2025 | 20 | 0.230 |
Why?
| | Radiometry | 3 | 2016 | 125 | 0.230 |
Why?
| | Organs at Risk | 3 | 2022 | 71 | 0.230 |
Why?
| | Energy-Generating Resources | 1 | 2025 | 1 | 0.230 |
Why?
| | Renewable Energy | 1 | 2025 | 2 | 0.230 |
Why?
| | Hindlimb | 2 | 2004 | 33 | 0.230 |
Why?
| | Tyrosine-tRNA Ligase | 1 | 2024 | 1 | 0.220 |
Why?
| | Ovarian Neoplasms | 2 | 2008 | 459 | 0.220 |
Why?
| | Administration, Oral | 6 | 2024 | 456 | 0.220 |
Why?
| | Hydrogen-Ion Concentration | 5 | 2005 | 169 | 0.220 |
Why?
| | Doxorubicin | 2 | 2024 | 247 | 0.220 |
Why?
| | Cell Culture Techniques | 2 | 2019 | 99 | 0.220 |
Why?
| | Antimalarials | 1 | 2024 | 34 | 0.220 |
Why?
| | Disease Progression | 4 | 2019 | 880 | 0.210 |
Why?
| | Endocytosis | 1 | 2024 | 47 | 0.210 |
Why?
| | Oxidants, Photochemical | 1 | 2004 | 3 | 0.210 |
Why?
| | Smog | 1 | 2004 | 5 | 0.210 |
Why?
| | Floods | 2 | 2021 | 3 | 0.210 |
Why?
| | Clinical Trials as Topic | 3 | 2023 | 466 | 0.210 |
Why?
| | Porphyrins | 1 | 2023 | 9 | 0.210 |
Why?
| | Oxidants | 1 | 2004 | 51 | 0.210 |
Why?
| | Vascular Endothelial Growth Factor A | 5 | 2017 | 189 | 0.210 |
Why?
| | Nitroimidazoles | 2 | 2015 | 16 | 0.210 |
Why?
| | Proteomics | 4 | 2021 | 336 | 0.210 |
Why?
| | Photochemotherapy | 1 | 2023 | 32 | 0.200 |
Why?
| | Sulfur Oxides | 1 | 2023 | 1 | 0.200 |
Why?
| | Gulf of Mexico | 1 | 2023 | 7 | 0.200 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2008 | 52 | 0.200 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2023 | 212 | 0.200 |
Why?
| | Partial Pressure | 3 | 2011 | 14 | 0.200 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2021 | 141 | 0.200 |
Why?
| | Tumor Burden | 3 | 2010 | 132 | 0.190 |
Why?
| | Halogens | 1 | 2022 | 3 | 0.190 |
Why?
| | Phosphatidylethanolamines | 1 | 2022 | 10 | 0.190 |
Why?
| | Organic Anion Transporters | 1 | 2022 | 1 | 0.190 |
Why?
| | Lipid Bilayers | 1 | 2022 | 12 | 0.190 |
Why?
| | Bile | 1 | 2022 | 23 | 0.190 |
Why?
| | Chloral Hydrate | 1 | 2022 | 18 | 0.190 |
Why?
| | Environmental Exposure | 2 | 2022 | 222 | 0.190 |
Why?
| | Parasites | 1 | 2002 | 3 | 0.190 |
Why?
| | Water Pollution | 1 | 2002 | 9 | 0.190 |
Why?
| | Protein Binding | 5 | 2020 | 670 | 0.190 |
Why?
| | Glucocorticoids | 2 | 2022 | 236 | 0.190 |
Why?
| | Receptors, Growth Factor | 1 | 2002 | 7 | 0.190 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2002 | 8 | 0.190 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 2002 | 5 | 0.190 |
Why?
| | Biological Transport | 2 | 2021 | 150 | 0.180 |
Why?
| | X-Rays | 3 | 2016 | 55 | 0.180 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 3 | 2007 | 11 | 0.180 |
Why?
| | Low Back Pain | 1 | 2022 | 31 | 0.180 |
Why?
| | Naphthoquinones | 3 | 2007 | 10 | 0.180 |
Why?
| | Protons | 1 | 2022 | 75 | 0.180 |
Why?
| | Bone Resorption | 2 | 2022 | 304 | 0.180 |
Why?
| | Liver Neoplasms | 2 | 2023 | 346 | 0.180 |
Why?
| | Cholesterol | 1 | 2022 | 161 | 0.180 |
Why?
| | Postmenopause | 1 | 2022 | 85 | 0.180 |
Why?
| | Pyrroles | 1 | 2002 | 73 | 0.180 |
Why?
| | Boron Compounds | 1 | 2021 | 20 | 0.180 |
Why?
| | Neoplasm Proteins | 3 | 2017 | 330 | 0.180 |
Why?
| | Nucleotides, Cyclic | 1 | 2021 | 5 | 0.170 |
Why?
| | High-Intensity Focused Ultrasound Ablation | 2 | 2011 | 14 | 0.170 |
Why?
| | Spheroids, Cellular | 3 | 2019 | 27 | 0.170 |
Why?
| | Optical Imaging | 2 | 2020 | 27 | 0.170 |
Why?
| | Endosomes | 1 | 2021 | 35 | 0.170 |
Why?
| | Bone Remodeling | 1 | 2022 | 154 | 0.170 |
Why?
| | Radiation, Ionizing | 4 | 2018 | 101 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2021 | 23 | 0.170 |
Why?
| | Cells, Cultured | 4 | 2020 | 1569 | 0.170 |
Why?
| | Proprioception | 1 | 2020 | 7 | 0.170 |
Why?
| | Proteasome Inhibitors | 1 | 2021 | 104 | 0.170 |
Why?
| | Ankle | 1 | 2020 | 15 | 0.170 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 62 | 0.160 |
Why?
| | Spectrum Analysis | 1 | 2020 | 50 | 0.160 |
Why?
| | Chronic Pain | 1 | 2023 | 183 | 0.160 |
Why?
| | Proton Therapy | 1 | 2020 | 12 | 0.160 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 187 | 0.160 |
Why?
| | Thymus Gland | 1 | 2020 | 39 | 0.160 |
Why?
| | History, 21st Century | 1 | 2020 | 60 | 0.160 |
Why?
| | Adenosine Triphosphate | 1 | 2021 | 211 | 0.160 |
Why?
| | Cell Differentiation | 2 | 2020 | 681 | 0.160 |
Why?
| | Neural Stem Cells | 1 | 2020 | 33 | 0.160 |
Why?
| | Heavy Ion Radiotherapy | 1 | 2019 | 2 | 0.160 |
Why?
| | Receptor, TIE-2 | 2 | 2017 | 16 | 0.160 |
Why?
| | Spleen | 1 | 2020 | 166 | 0.160 |
Why?
| | Carcinoma, Lewis Lung | 1 | 2019 | 10 | 0.150 |
Why?
| | Public Health | 1 | 2002 | 231 | 0.150 |
Why?
| | Calixarenes | 2 | 2017 | 9 | 0.150 |
Why?
| | Osteogenesis | 1 | 2022 | 374 | 0.150 |
Why?
| | Whole-Body Irradiation | 1 | 2020 | 129 | 0.150 |
Why?
| | Cone-Beam Computed Tomography | 2 | 2016 | 29 | 0.150 |
Why?
| | Societies, Medical | 1 | 2020 | 207 | 0.150 |
Why?
| | Autoantibodies | 1 | 2020 | 120 | 0.150 |
Why?
| | Interleukin-6 | 2 | 2020 | 272 | 0.150 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 136 | 0.150 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 1583 | 0.150 |
Why?
| | Cyclonic Storms | 2 | 2017 | 8 | 0.150 |
Why?
| | Drug Evaluation, Preclinical | 3 | 2015 | 142 | 0.150 |
Why?
| | Preservation, Biological | 1 | 2018 | 9 | 0.150 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 89 | 0.150 |
Why?
| | Membrane Proteins | 1 | 2021 | 333 | 0.150 |
Why?
| | Astrocytes | 1 | 2020 | 139 | 0.140 |
Why?
| | Ephrin-B2 | 1 | 2018 | 5 | 0.140 |
Why?
| | Paracrine Communication | 1 | 2018 | 13 | 0.140 |
Why?
| | Cystic Fibrosis | 1 | 2021 | 155 | 0.140 |
Why?
| | Methionine Adenosyltransferase | 1 | 2018 | 19 | 0.140 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 145 | 0.140 |
Why?
| | Microinjections | 1 | 2018 | 34 | 0.140 |
Why?
| | Treatment Outcome | 5 | 2020 | 5595 | 0.140 |
Why?
| | Myocytes, Cardiac | 1 | 2019 | 147 | 0.140 |
Why?
| | Biological Assay | 1 | 2018 | 46 | 0.140 |
Why?
| | Environmental Pollutants | 1 | 2020 | 110 | 0.140 |
Why?
| | Lipopolysaccharides | 1 | 2019 | 203 | 0.140 |
Why?
| | Receptors, Fc | 1 | 2018 | 10 | 0.140 |
Why?
| | Calibration | 1 | 2018 | 58 | 0.140 |
Why?
| | Prostatic Neoplasms | 2 | 2013 | 401 | 0.140 |
Why?
| | Galectins | 1 | 2018 | 7 | 0.140 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2018 | 47 | 0.140 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2018 | 3 | 0.140 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2018 | 107 | 0.140 |
Why?
| | Nucleosides | 1 | 2018 | 5 | 0.140 |
Why?
| | Indazoles | 1 | 2018 | 47 | 0.140 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 110 | 0.140 |
Why?
| | Erythrocyte Membrane | 1 | 2017 | 14 | 0.140 |
Why?
| | California | 4 | 2010 | 93 | 0.140 |
Why?
| | Particle Size | 2 | 2024 | 76 | 0.140 |
Why?
| | Structure-Activity Relationship | 7 | 2021 | 396 | 0.130 |
Why?
| | Scavenger Receptors, Class E | 1 | 2019 | 204 | 0.130 |
Why?
| | Small Molecule Libraries | 1 | 2018 | 66 | 0.130 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2017 | 35 | 0.130 |
Why?
| | MicroRNAs | 1 | 2021 | 397 | 0.130 |
Why?
| | Models, Molecular | 4 | 2021 | 352 | 0.130 |
Why?
| | Natural Science Disciplines | 1 | 2017 | 2 | 0.130 |
Why?
| | Epitope Mapping | 1 | 2017 | 6 | 0.130 |
Why?
| | Vehicle Emissions | 1 | 2017 | 10 | 0.130 |
Why?
| | Receptors, Interleukin-6 | 1 | 2017 | 22 | 0.130 |
Why?
| | Muscle, Skeletal | 2 | 2020 | 815 | 0.130 |
Why?
| | United States | 5 | 2025 | 5409 | 0.130 |
Why?
| | Silver | 1 | 2017 | 49 | 0.130 |
Why?
| | Pyridazines | 2 | 2008 | 10 | 0.130 |
Why?
| | Bacteria | 1 | 2018 | 226 | 0.130 |
Why?
| | Myocardial Infarction | 1 | 2021 | 445 | 0.130 |
Why?
| | Random Allocation | 2 | 2015 | 284 | 0.130 |
Why?
| | Epithelial Cells | 1 | 2018 | 218 | 0.130 |
Why?
| | Sulfonamides | 1 | 2018 | 139 | 0.130 |
Why?
| | Ammonia | 1 | 2017 | 89 | 0.130 |
Why?
| | Biomass | 1 | 2016 | 22 | 0.130 |
Why?
| | Social Environment | 1 | 2017 | 82 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 1043 | 0.120 |
Why?
| | Dendritic Cells | 1 | 2017 | 133 | 0.120 |
Why?
| | Mice, Inbred Strains | 3 | 2013 | 163 | 0.120 |
Why?
| | Antibodies | 1 | 2017 | 147 | 0.120 |
Why?
| | Linear Models | 2 | 2016 | 287 | 0.120 |
Why?
| | Radiation Protection | 1 | 2016 | 46 | 0.120 |
Why?
| | Computer Simulation | 4 | 2025 | 290 | 0.120 |
Why?
| | Extraterrestrial Environment | 1 | 2016 | 7 | 0.120 |
Why?
| | Neoplasm Transplantation | 2 | 2007 | 86 | 0.120 |
Why?
| | Chemistry, Organic | 2 | 2019 | 2 | 0.120 |
Why?
| | Organ Specificity | 1 | 2016 | 115 | 0.120 |
Why?
| | Extracellular Fluid | 1 | 2015 | 14 | 0.120 |
Why?
| | Tomography, Spiral Computed | 1 | 2016 | 55 | 0.120 |
Why?
| | Multiple Myeloma | 1 | 2010 | 3082 | 0.120 |
Why?
| | Microbubbles | 1 | 2015 | 27 | 0.120 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2016 | 89 | 0.120 |
Why?
| | Organ Sparing Treatments | 1 | 2016 | 58 | 0.110 |
Why?
| | Cell Count | 1 | 2015 | 141 | 0.110 |
Why?
| | Sulfuric Acids | 1 | 2015 | 8 | 0.110 |
Why?
| | Stromal Cells | 1 | 2015 | 77 | 0.110 |
Why?
| | Pressure | 1 | 2015 | 102 | 0.110 |
Why?
| | Rabbits | 3 | 2010 | 372 | 0.110 |
Why?
| | Necrosis | 3 | 2013 | 169 | 0.110 |
Why?
| | Feasibility Studies | 3 | 2025 | 411 | 0.110 |
Why?
| | Biomedical Research | 1 | 2018 | 267 | 0.110 |
Why?
| | Tandem Mass Spectrometry | 3 | 2017 | 254 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 145 | 0.110 |
Why?
| | Carbon Dioxide | 2 | 2005 | 97 | 0.110 |
Why?
| | Cisplatin | 2 | 2024 | 282 | 0.110 |
Why?
| | Contrast Media | 1 | 2015 | 178 | 0.110 |
Why?
| | Mexico | 1 | 2014 | 38 | 0.110 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 505 | 0.100 |
Why?
| | Hot Temperature | 3 | 2013 | 202 | 0.100 |
Why?
| | HEK293 Cells | 3 | 2020 | 235 | 0.100 |
Why?
| | Animals, Inbred Strains | 1 | 2013 | 5 | 0.100 |
Why?
| | Ultrasonography | 1 | 2015 | 426 | 0.100 |
Why?
| | DNA Methylation | 1 | 2018 | 592 | 0.100 |
Why?
| | Nanoconjugates | 1 | 2013 | 1 | 0.100 |
Why?
| | Ions | 2 | 2024 | 31 | 0.100 |
Why?
| | Food, Genetically Modified | 1 | 2013 | 1 | 0.100 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2013 | 4 | 0.100 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 22 | 0.100 |
Why?
| | Societies, Scientific | 1 | 2013 | 14 | 0.100 |
Why?
| | Food Labeling | 1 | 2013 | 7 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 181 | 0.100 |
Why?
| | Nanospheres | 1 | 2013 | 4 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2015 | 282 | 0.100 |
Why?
| | Nanotechnology | 1 | 2013 | 31 | 0.100 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2013 | 46 | 0.100 |
Why?
| | Nutrition Policy | 1 | 2013 | 40 | 0.100 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1112 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 579 | 0.090 |
Why?
| | Blotting, Western | 1 | 2013 | 587 | 0.090 |
Why?
| | Mice, Inbred C57BL | 4 | 2020 | 1925 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 412 | 0.090 |
Why?
| | Film Dosimetry | 1 | 2012 | 15 | 0.090 |
Why?
| | Glucose | 2 | 2011 | 361 | 0.090 |
Why?
| | Surface Plasmon Resonance | 3 | 2017 | 19 | 0.090 |
Why?
| | RNA, Messenger | 2 | 2013 | 1133 | 0.090 |
Why?
| | Middle Aged | 6 | 2024 | 13419 | 0.090 |
Why?
| | North Carolina | 2 | 2022 | 53 | 0.090 |
Why?
| | Gold Colloid | 2 | 2011 | 2 | 0.090 |
Why?
| | Acids | 1 | 2011 | 9 | 0.090 |
Why?
| | Isomerism | 1 | 2011 | 23 | 0.090 |
Why?
| | Gene Expression Regulation | 3 | 2021 | 1003 | 0.090 |
Why?
| | Adult | 6 | 2024 | 14534 | 0.090 |
Why?
| | Immunohistochemistry | 2 | 2020 | 975 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2011 | 129 | 0.090 |
Why?
| | Copper | 1 | 2011 | 47 | 0.090 |
Why?
| | Aldehydes | 1 | 2011 | 81 | 0.090 |
Why?
| | Feces | 2 | 2024 | 159 | 0.090 |
Why?
| | Acenaphthenes | 1 | 2010 | 1 | 0.080 |
Why?
| | Nitrogen Oxides | 1 | 2010 | 3 | 0.080 |
Why?
| | Drug Screening Assays, Antitumor | 3 | 2024 | 136 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2013 | 321 | 0.080 |
Why?
| | Positron-Emission Tomography | 1 | 2012 | 298 | 0.080 |
Why?
| | Myosins | 1 | 2010 | 19 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 1180 | 0.080 |
Why?
| | Bone Transplantation | 1 | 2010 | 43 | 0.080 |
Why?
| | Isoxazoles | 1 | 2009 | 16 | 0.080 |
Why?
| | Nitrous Acid | 1 | 2009 | 1 | 0.080 |
Why?
| | Free Radicals | 1 | 2009 | 27 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 71 | 0.080 |
Why?
| | Actins | 1 | 2010 | 114 | 0.080 |
Why?
| | Microcirculation | 1 | 2010 | 63 | 0.080 |
Why?
| | Acetylcysteine | 1 | 2010 | 104 | 0.080 |
Why?
| | Protein Transport | 1 | 2010 | 168 | 0.080 |
Why?
| | Naphthalenes | 1 | 2010 | 121 | 0.080 |
Why?
| | Aged | 5 | 2022 | 10429 | 0.080 |
Why?
| | Formaldehyde | 1 | 2009 | 51 | 0.080 |
Why?
| | Dogs | 2 | 2025 | 186 | 0.080 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2009 | 58 | 0.080 |
Why?
| | Coculture Techniques | 2 | 2020 | 146 | 0.070 |
Why?
| | Prospective Studies | 3 | 2023 | 2411 | 0.070 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2016 | 122 | 0.070 |
Why?
| | Glycolysis | 2 | 2021 | 76 | 0.070 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2009 | 39 | 0.070 |
Why?
| | Young Adult | 3 | 2024 | 4511 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 | 2 | 2008 | 21 | 0.070 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2008 | 10 | 0.070 |
Why?
| | Growth Inhibitors | 2 | 2009 | 26 | 0.070 |
Why?
| | Up-Regulation | 2 | 2007 | 456 | 0.070 |
Why?
| | Nerve Tissue Proteins | 2 | 2020 | 193 | 0.070 |
Why?
| | Methotrexate | 1 | 2009 | 78 | 0.070 |
Why?
| | Evoked Potentials, Auditory, Brain Stem | 1 | 2008 | 26 | 0.070 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2009 | 141 | 0.070 |
Why?
| | STAT3 Transcription Factor | 2 | 2020 | 89 | 0.070 |
Why?
| | Drinking | 2 | 2020 | 42 | 0.070 |
Why?
| | Alkynes | 1 | 2008 | 6 | 0.070 |
Why?
| | Pyrrolidines | 1 | 2008 | 65 | 0.070 |
Why?
| | Cytotoxins | 1 | 2008 | 15 | 0.070 |
Why?
| | Regional Blood Flow | 2 | 2005 | 112 | 0.070 |
Why?
| | Cryosurgery | 2 | 2011 | 36 | 0.070 |
Why?
| | Drug Synergism | 2 | 2005 | 147 | 0.070 |
Why?
| | Chemical Fractionation | 1 | 2007 | 17 | 0.070 |
Why?
| | Fluorescence | 2 | 2018 | 30 | 0.070 |
Why?
| | Toxicity Tests | 1 | 2008 | 57 | 0.070 |
Why?
| | Skin | 2 | 2009 | 419 | 0.070 |
Why?
| | Cost-Benefit Analysis | 2 | 2021 | 274 | 0.070 |
Why?
| | Enzyme Activation | 2 | 2005 | 267 | 0.070 |
Why?
| | Oxidative Stress | 1 | 2012 | 819 | 0.070 |
Why?
| | Neurons | 2 | 2020 | 394 | 0.070 |
Why?
| | In Situ Nick-End Labeling | 2 | 2004 | 54 | 0.070 |
Why?
| | Histones | 2 | 2020 | 318 | 0.070 |
Why?
| | Sesquiterpenes | 1 | 2008 | 90 | 0.060 |
Why?
| | Sulfides | 2 | 2018 | 29 | 0.060 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2008 | 82 | 0.060 |
Why?
| | Angiopoietin-1 | 2 | 2017 | 16 | 0.060 |
Why?
| | Concept Formation | 1 | 2006 | 13 | 0.060 |
Why?
| | Angiopoietin-2 | 2 | 2017 | 17 | 0.060 |
Why?
| | Fibroblast Growth Factor 2 | 2 | 2017 | 35 | 0.060 |
Why?
| | Lasers | 2 | 2019 | 64 | 0.060 |
Why?
| | Wetlands | 2 | 2017 | 6 | 0.060 |
Why?
| | Interleukin-2 | 1 | 2006 | 69 | 0.060 |
Why?
| | Coral Reefs | 2 | 2017 | 3 | 0.060 |
Why?
| | Interleukin-8 | 1 | 2006 | 85 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 2 | 2017 | 88 | 0.060 |
Why?
| | Temperature | 3 | 2018 | 165 | 0.060 |
Why?
| | Sarcoma | 1 | 2007 | 72 | 0.060 |
Why?
| | Mice, Inbred A | 2 | 2003 | 14 | 0.060 |
Why?
| | Signal-To-Noise Ratio | 1 | 2025 | 23 | 0.060 |
Why?
| | Electrophoresis | 1 | 2005 | 16 | 0.060 |
Why?
| | Sensitivity and Specificity | 3 | 2016 | 867 | 0.060 |
Why?
| | Neoadjuvant Therapy | 2 | 2017 | 124 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2007 | 238 | 0.060 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 64 | 0.060 |
Why?
| | Tumor Suppressor Proteins | 1 | 2006 | 130 | 0.060 |
Why?
| | Carbon | 1 | 2005 | 60 | 0.060 |
Why?
| | Electricity | 1 | 2025 | 7 | 0.060 |
Why?
| | Alkanes | 1 | 2005 | 10 | 0.060 |
Why?
| | Neoplasm Staging | 2 | 2019 | 774 | 0.060 |
Why?
| | Public Policy | 2 | 2015 | 39 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 146 | 0.060 |
Why?
| | Photoacoustic Techniques | 2 | 2016 | 24 | 0.060 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 71 | 0.060 |
Why?
| | Cell Cycle Proteins | 1 | 2006 | 170 | 0.060 |
Why?
| | Niacinamide | 1 | 2005 | 24 | 0.060 |
Why?
| | Colorectal Neoplasms | 2 | 2006 | 302 | 0.060 |
Why?
| | Transplantation, Heterologous | 2 | 2021 | 78 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 647 | 0.050 |
Why?
| | Organelles | 1 | 2024 | 11 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2009 | 1367 | 0.050 |
Why?
| | Protozoan Proteins | 1 | 2024 | 33 | 0.050 |
Why?
| | Rats, Inbred F344 | 1 | 2005 | 194 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2005 | 108 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2024 | 48 | 0.050 |
Why?
| | Amines | 1 | 2004 | 38 | 0.050 |
Why?
| | MCF-7 Cells | 1 | 2024 | 65 | 0.050 |
Why?
| | Lichen Planus, Oral | 1 | 2004 | 1 | 0.050 |
Why?
| | Materials Testing | 1 | 2024 | 55 | 0.050 |
Why?
| | Kidney Diseases | 1 | 2007 | 230 | 0.050 |
Why?
| | Leukoplakia, Oral | 1 | 2004 | 6 | 0.050 |
Why?
| | Drug Combinations | 2 | 2018 | 138 | 0.050 |
Why?
| | Photochemistry | 1 | 2004 | 8 | 0.050 |
Why?
| | Binding Sites | 2 | 2021 | 373 | 0.050 |
Why?
| | Buthionine Sulfoximine | 1 | 2024 | 13 | 0.050 |
Why?
| | Hydrocarbons | 1 | 2004 | 13 | 0.050 |
Why?
| | Biological Availability | 1 | 2024 | 107 | 0.050 |
Why?
| | Cations | 1 | 2023 | 9 | 0.050 |
Why?
| | Carboplatin | 1 | 2024 | 57 | 0.050 |
Why?
| | Biocompatible Materials | 1 | 2024 | 67 | 0.050 |
Why?
| | Phosphorylation | 3 | 2017 | 533 | 0.050 |
Why?
| | Monoterpenes | 1 | 2003 | 5 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2004 | 198 | 0.050 |
Why?
| | Photosensitizing Agents | 1 | 2023 | 21 | 0.050 |
Why?
| | Crystallography, X-Ray | 2 | 2018 | 155 | 0.050 |
Why?
| | Mass Spectrometry | 2 | 2019 | 294 | 0.050 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2024 | 83 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 114 | 0.050 |
Why?
| | Organic Chemicals | 1 | 2003 | 15 | 0.050 |
Why?
| | Hepatitis B virus | 1 | 2023 | 20 | 0.050 |
Why?
| | Sphingomyelin Phosphodiesterase | 1 | 2003 | 11 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 34 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2006 | 423 | 0.050 |
Why?
| | Prognosis | 2 | 2009 | 2118 | 0.050 |
Why?
| | G2 Phase | 1 | 2003 | 14 | 0.050 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 262 | 0.050 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2003 | 33 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2016 | 38 | 0.050 |
Why?
| | Quinazolines | 1 | 2003 | 34 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2004 | 547 | 0.050 |
Why?
| | Anions | 1 | 2022 | 6 | 0.050 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2004 | 228 | 0.050 |
Why?
| | Interferons | 1 | 2022 | 39 | 0.050 |
Why?
| | Consensus | 1 | 2023 | 206 | 0.050 |
Why?
| | Injections, Epidural | 1 | 2022 | 10 | 0.050 |
Why?
| | Acetone | 1 | 2022 | 7 | 0.050 |
Why?
| | Osteocalcin | 1 | 2022 | 45 | 0.050 |
Why?
| | Rifampin | 1 | 2022 | 57 | 0.050 |
Why?
| | Probability | 2 | 2016 | 171 | 0.050 |
Why?
| | Polyphosphates | 1 | 2022 | 2 | 0.050 |
Why?
| | Hepatocytes | 1 | 2023 | 188 | 0.050 |
Why?
| | Pain Measurement | 1 | 2023 | 259 | 0.050 |
Why?
| | Heating | 1 | 2022 | 5 | 0.050 |
Why?
| | Inositol | 1 | 2022 | 19 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 26 | 0.050 |
Why?
| | Propionates | 1 | 2002 | 23 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2022 | 1219 | 0.050 |
Why?
| | Hydrocortisone | 1 | 2022 | 113 | 0.050 |
Why?
| | Demography | 1 | 2022 | 91 | 0.050 |
Why?
| | Ferrets | 1 | 2021 | 7 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2022 | 124 | 0.040 |
Why?
| | Estuaries | 1 | 2021 | 2 | 0.040 |
Why?
| | Bays | 1 | 2021 | 2 | 0.040 |
Why?
| | Hydrodynamics | 1 | 2021 | 8 | 0.040 |
Why?
| | Pain Management | 1 | 2023 | 185 | 0.040 |
Why?
| | San Francisco | 1 | 2021 | 12 | 0.040 |
Why?
| | Models, Economic | 1 | 2021 | 18 | 0.040 |
Why?
| | Income | 1 | 2022 | 106 | 0.040 |
Why?
| | Catalytic Domain | 1 | 2021 | 60 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 90 | 0.040 |
Why?
| | Protein Structure, Tertiary | 2 | 2017 | 252 | 0.040 |
Why?
| | Cricetinae | 1 | 2021 | 190 | 0.040 |
Why?
| | Cell Division | 1 | 2002 | 289 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2021 | 3494 | 0.040 |
Why?
| | Half-Life | 1 | 2021 | 86 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 350 | 0.040 |
Why?
| | Phosphates | 1 | 2021 | 51 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2021 | 73 | 0.040 |
Why?
| | Micronucleus Tests | 1 | 2020 | 6 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 120 | 0.040 |
Why?
| | Analgesics, Opioid | 1 | 2007 | 622 | 0.040 |
Why?
| | ROC Curve | 1 | 2021 | 246 | 0.040 |
Why?
| | Cell Line, Transformed | 1 | 2021 | 73 | 0.040 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 93 | 0.040 |
Why?
| | Software | 2 | 2016 | 280 | 0.040 |
Why?
| | Skin Temperature | 1 | 2020 | 17 | 0.040 |
Why?
| | Feedback, Physiological | 1 | 2020 | 12 | 0.040 |
Why?
| | Catecholamines | 1 | 2020 | 44 | 0.040 |
Why?
| | Limbic Encephalitis | 1 | 2020 | 2 | 0.040 |
Why?
| | Elastin | 1 | 2020 | 24 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 89 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2020 | 62 | 0.040 |
Why?
| | ADAM Proteins | 1 | 2020 | 21 | 0.040 |
Why?
| | Autoantigens | 1 | 2020 | 46 | 0.040 |
Why?
| | HeLa Cells | 1 | 2020 | 243 | 0.040 |
Why?
| | Bone Density | 1 | 2022 | 397 | 0.040 |
Why?
| | Epitopes | 1 | 2020 | 61 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2021 | 179 | 0.040 |
Why?
| | Cytoprotection | 1 | 2019 | 32 | 0.040 |
Why?
| | Facility Design and Construction | 1 | 2019 | 3 | 0.040 |
Why?
| | Muscle Contraction | 1 | 2020 | 114 | 0.040 |
Why?
| | Endothelium | 1 | 2019 | 38 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2019 | 59 | 0.040 |
Why?
| | Energy Intake | 1 | 2020 | 186 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2002 | 219 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2019 | 57 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2020 | 184 | 0.040 |
Why?
| | Glioma | 1 | 2020 | 83 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2004 | 500 | 0.040 |
Why?
| | Diffusion Chambers, Culture | 1 | 2018 | 7 | 0.040 |
Why?
| | Culture Media, Serum-Free | 1 | 2018 | 11 | 0.040 |
Why?
| | Swine | 2 | 2011 | 440 | 0.040 |
Why?
| | Program Development | 1 | 2019 | 165 | 0.040 |
Why?
| | Culture Media, Conditioned | 1 | 2018 | 49 | 0.040 |
Why?
| | Hep G2 Cells | 1 | 2018 | 38 | 0.040 |
Why?
| | Laminin | 1 | 2018 | 20 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2004 | 2318 | 0.040 |
Why?
| | Flavin-Adenine Dinucleotide | 1 | 2018 | 5 | 0.040 |
Why?
| | Dextrans | 1 | 2018 | 16 | 0.040 |
Why?
| | Allosteric Site | 1 | 2018 | 2 | 0.040 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 35 | 0.040 |
Why?
| | Calcium-Binding Proteins | 1 | 2018 | 58 | 0.040 |
Why?
| | Body Weight | 1 | 2020 | 524 | 0.040 |
Why?
| | Hippocampus | 1 | 2020 | 195 | 0.040 |
Why?
| | Specimen Handling | 1 | 2018 | 63 | 0.040 |
Why?
| | Surface Properties | 1 | 2018 | 61 | 0.040 |
Why?
| | NAD | 1 | 2018 | 45 | 0.040 |
Why?
| | Proteoglycans | 1 | 2018 | 86 | 0.030 |
Why?
| | Imides | 1 | 2018 | 1 | 0.030 |
Why?
| | Mid-Atlantic Region | 1 | 2017 | 4 | 0.030 |
Why?
| | New England | 1 | 2017 | 10 | 0.030 |
Why?
| | Carbohydrates | 1 | 2018 | 42 | 0.030 |
Why?
| | Autophagy | 1 | 2019 | 199 | 0.030 |
Why?
| | Human Activities | 1 | 2017 | 7 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2017 | 11 | 0.030 |
Why?
| | Caco-2 Cells | 1 | 2017 | 31 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 237 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2018 | 111 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2018 | 86 | 0.030 |
Why?
| | Ligands | 1 | 2018 | 203 | 0.030 |
Why?
| | Cooperative Behavior | 1 | 2019 | 233 | 0.030 |
Why?
| | Ubiquitin | 1 | 2018 | 70 | 0.030 |
Why?
| | Nanotubes | 1 | 2017 | 17 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2018 | 202 | 0.030 |
Why?
| | Phagocytosis | 1 | 2017 | 59 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 279 | 0.030 |
Why?
| | Drug Interactions | 1 | 2017 | 196 | 0.030 |
Why?
| | Collagen | 1 | 2018 | 215 | 0.030 |
Why?
| | Disasters | 1 | 2017 | 19 | 0.030 |
Why?
| | Inflammation | 1 | 2021 | 652 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2017 | 48 | 0.030 |
Why?
| | Cohort Studies | 1 | 2021 | 1557 | 0.030 |
Why?
| | Cricetulus | 1 | 2017 | 101 | 0.030 |
Why?
| | Gene Frequency | 1 | 2017 | 97 | 0.030 |
Why?
| | CHO Cells | 1 | 2017 | 124 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 405 | 0.030 |
Why?
| | Pyrazoles | 1 | 2018 | 123 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 245 | 0.030 |
Why?
| | Fires | 1 | 2016 | 16 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2016 | 8 | 0.030 |
Why?
| | DNA Repair | 1 | 2018 | 197 | 0.030 |
Why?
| | Taxoids | 1 | 2016 | 38 | 0.030 |
Why?
| | Interleukin-1alpha | 1 | 2016 | 10 | 0.030 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2016 | 25 | 0.030 |
Why?
| | Radiation Pneumonitis | 1 | 2016 | 11 | 0.030 |
Why?
| | Poisson Distribution | 1 | 2016 | 36 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2016 | 68 | 0.030 |
Why?
| | Hindlimb Suspension | 1 | 2016 | 37 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 391 | 0.030 |
Why?
| | Diet | 1 | 2020 | 610 | 0.030 |
Why?
| | Particle Accelerators | 1 | 2016 | 51 | 0.030 |
Why?
| | Dicumarol | 2 | 2005 | 3 | 0.030 |
Why?
| | Palinuridae | 1 | 2015 | 1 | 0.030 |
Why?
| | Belize | 1 | 2015 | 2 | 0.030 |
Why?
| | Marine Biology | 1 | 2015 | 3 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2016 | 134 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 2016 | 178 | 0.030 |
Why?
| | Ecology | 1 | 2015 | 18 | 0.030 |
Why?
| | Carbonic Anhydrases | 1 | 2015 | 3 | 0.030 |
Why?
| | Molecular Structure | 2 | 2008 | 320 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2015 | 58 | 0.030 |
Why?
| | Recreation | 1 | 2015 | 21 | 0.030 |
Why?
| | Muscular Atrophy | 1 | 2016 | 73 | 0.030 |
Why?
| | Genotype | 1 | 2017 | 563 | 0.030 |
Why?
| | Sulfur Dioxide | 1 | 2015 | 4 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2018 | 324 | 0.030 |
Why?
| | Norepinephrine | 1 | 2015 | 106 | 0.030 |
Why?
| | Models, Animal | 1 | 2016 | 233 | 0.030 |
Why?
| | Epinephrine | 1 | 2015 | 92 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2017 | 910 | 0.030 |
Why?
| | Risk | 1 | 2015 | 306 | 0.030 |
Why?
| | Weight Gain | 1 | 2016 | 245 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2016 | 195 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 2 | 2004 | 75 | 0.030 |
Why?
| | Culture Media | 2 | 2004 | 97 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 830 | 0.020 |
Why?
| | Models, Immunological | 1 | 2013 | 8 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 33 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 580 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2013 | 71 | 0.020 |
Why?
| | Light | 1 | 2013 | 51 | 0.020 |
Why?
| | Decision Making | 1 | 2015 | 278 | 0.020 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2013 | 76 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2016 | 1544 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 667 | 0.020 |
Why?
| | Mutation | 1 | 2018 | 1337 | 0.020 |
Why?
| | Computer-Aided Design | 1 | 2011 | 20 | 0.020 |
Why?
| | Equipment Failure Analysis | 1 | 2011 | 43 | 0.020 |
Why?
| | Adjuvants, Pharmaceutic | 1 | 2011 | 5 | 0.020 |
Why?
| | Phantoms, Imaging | 1 | 2011 | 112 | 0.020 |
Why?
| | Equipment Design | 1 | 2011 | 290 | 0.020 |
Why?
| | Volatilization | 1 | 2010 | 5 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2010 | 71 | 0.020 |
Why?
| | Solvents | 1 | 2010 | 32 | 0.020 |
Why?
| | Geography | 1 | 2010 | 65 | 0.020 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2009 | 33 | 0.020 |
Why?
| | Air | 1 | 2009 | 22 | 0.020 |
Why?
| | Amides | 1 | 2009 | 36 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2022 | 6819 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2009 | 69 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2009 | 21 | 0.020 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 27 | 0.020 |
Why?
| | Thermal Conductivity | 1 | 2009 | 7 | 0.020 |
Why?
| | Mammary Glands, Animal | 1 | 2009 | 68 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2010 | 333 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2009 | 89 | 0.020 |
Why?
| | Pharmacokinetics | 1 | 2008 | 14 | 0.020 |
Why?
| | Models, Statistical | 1 | 2010 | 229 | 0.020 |
Why?
| | Child | 1 | 2021 | 7379 | 0.020 |
Why?
| | Guinea Pigs | 1 | 2008 | 75 | 0.020 |
Why?
| | Drug Design | 1 | 2009 | 121 | 0.020 |
Why?
| | Isatin | 1 | 2008 | 1 | 0.020 |
Why?
| | Bone Marrow | 1 | 2010 | 359 | 0.020 |
Why?
| | Auditory Threshold | 1 | 2008 | 54 | 0.020 |
Why?
| | Weight Loss | 1 | 2010 | 257 | 0.020 |
Why?
| | Glycosylphosphatidylinositols | 1 | 2007 | 14 | 0.020 |
Why?
| | Recurrence | 1 | 2009 | 694 | 0.020 |
Why?
| | Rubidium | 1 | 2006 | 4 | 0.020 |
Why?
| | Isoelectric Point | 1 | 2005 | 4 | 0.010 |
Why?
| | Isoelectric Focusing | 1 | 2005 | 8 | 0.010 |
Why?
| | Peptide Mapping | 1 | 2005 | 25 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2009 | 1049 | 0.010 |
Why?
| | Caffeine | 1 | 2006 | 64 | 0.010 |
Why?
| | Air Movements | 1 | 2005 | 1 | 0.010 |
Why?
| | Liver | 1 | 2011 | 1150 | 0.010 |
Why?
| | Cell Cycle | 1 | 2006 | 237 | 0.010 |
Why?
| | Quality Control | 1 | 2005 | 98 | 0.010 |
Why?
| | Tumor Stem Cell Assay | 1 | 2004 | 16 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2007 | 347 | 0.010 |
Why?
| | Tennessee | 1 | 2003 | 37 | 0.010 |
Why?
| | HL-60 Cells | 1 | 2003 | 19 | 0.010 |
Why?
| | Solubility | 1 | 2003 | 83 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2009 | 591 | 0.010 |
Why?
| | Cyclin B | 1 | 2003 | 4 | 0.010 |
Why?
| | CDC2 Protein Kinase | 1 | 2003 | 15 | 0.010 |
Why?
| | Cyclin B1 | 1 | 2003 | 7 | 0.010 |
Why?
| | Water | 1 | 2003 | 87 | 0.010 |
Why?
| | Heat-Shock Proteins | 1 | 2003 | 104 | 0.010 |
Why?
|
|
Griffin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|